Dr Prem Global Healthcare Logo

An anti-clotting drug to save more lives than standard treatment

<![CDATA[

***An anti-clotting drug to save more lives than standard treatment.*

An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market.

Although Eliquis will be third to market among a wave of new oral anticoagulants, the data presented Sunday at Europe’s biggest medical meeting means it could now be viewed as the best in class.

People with dangerously irregular heart rhythms given Eliquis were 21 percent less likely to suffer strokes than those on decades-old warfarin, a problematic drug first developed as rat poison that requires regular blood tests.

It also produced a 31 percent relative reduction in the risk of major bleeding — especially bleeding in the brain — and an 11 percent reduction in risk of death from any cause, results from a 18,000-patient study lasting nearly two years showed.

Ref and Read more: http://www.reuters.com/article/2011/08/28/us-heart-bristol-pfizer-idUSTRE77R0LF20110828

]]>

Recent Articles:

Scroll to Top